Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

86499-35-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 86499-35-6 Structure
  • Basic information

    1. Product Name: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one
    2. Synonyms: 3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENAZEPIN-2-ONE;3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE HYDROCHLORIDE;3-AMINO-1,3,4,5-TETRAHYDRO-2H-1-BENZAZEPIN-2-ONE;3-AMINO-1,3,4,5-TETRAHYDRO-BENZO[B]AZEPIN-2-ONE;3-Amino-2,3,4,5-tetrahydro-2-oxo-2H-1-benzazepine;3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one;Benazepril Intermediate;3-amino-1,3,4,5-tetrahydro-2H-benzaone-2-one
    3. CAS NO:86499-35-6
    4. Molecular Formula: C10H12N2O
    5. Molecular Weight: 176.22
    6. EINECS: N/A
    7. Product Categories: pharmacetical
    8. Mol File: 86499-35-6.mol
  • Chemical Properties

    1. Melting Point: 193-195 °C
    2. Boiling Point: 377.5 °C at 760 mmHg
    3. Flash Point: 182.1 °C
    4. Appearance: /
    5. Density: 1.143 g/cm3
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C(protect from light)
    8. Solubility: N/A
    9. PKA: 14.57±0.40(Predicted)
    10. CAS DataBase Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(CAS DataBase Reference)
    11. NIST Chemistry Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)
    12. EPA Substance Registry System: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 86499-35-6(Hazardous Substances Data)

86499-35-6 Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 50, p. 3408, 1985 DOI: 10.1021/jo00218a034

Check Digit Verification of cas no

The CAS Registry Mumber 86499-35-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,4,9 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 86499-35:
(7*8)+(6*6)+(5*4)+(4*9)+(3*9)+(2*3)+(1*5)=186
186 % 10 = 6
So 86499-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O.ClH/c11-8-6-5-7-3-1-2-4-9(7)12-10(8)13;/h1-4,8H,5-6,11H2,(H,12,13);1H

86499-35-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-amino-1,3,4,5-tetrahydro-1-benzazepin-2-one

1.2 Other means of identification

Product number -
Other names 3-Amino-1,3,4,5-tetrahydro-benzo[b]azepin-2-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:86499-35-6 SDS

86499-35-6Relevant articles and documents

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

-

, (2014/09/03)

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Evaluation of a 125I-labelled benzazepinone derived voltage-gated sodium channel blocker for imaging with SPECT

Perez-Medina, Carlos,Patel, Niral,Robson, Mathew,Badar, Adam,Lythgoe, Mark F.,Arstad, Erik

supporting information, p. 9474 - 9480 (2013/01/15)

Voltage-gated sodium channels (VGSCs) are a family of transmembrane proteins that mediate fast neurotransmission, and are integral to sustain physiological conditions and higher cognitive functions. Imaging of VGSCs in vivo holds promise as a tool to elucidate operational functions in the brain and to aid the treatment of a wide range of neurological diseases. To assess the suitability of 1-benzazepin-2-one derived VGSC blockers for imaging, we have prepared a 125I-labelled analogue of BNZA and evaluated the tracer in vivo. In an automated patch-clamp assay, a diastereomeric mixture of the non-radioactive compound blocked the Nav1.2 and Nav1.7 VGSC isoforms with IC50 values of 4.1 ± 1.5 μM and 0.25 ± 0.07 μM, respectively. [3H]BTX displacement studies revealed a three-fold difference in affinity between the two diastereomers. Iodo-destannylation of a tin precursor with iodine-125 afforded the two diastereomerically pure tracers, which were used to assess binding to VGSCs in vivo by comparing their tissue distributions in mice. Whilst the results point to a lack of VGSC binding in vivo, SPECT imaging revealed highly localized uptake in the interscapular region, an area typically associated with brown adipose tissue, which in addition to high metabolic stability of the iodinated tracer, demonstrate the potential of 1-benzazepin-2-ones for in vivo imaging.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

-

, (2008/06/13)

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

-

, (2008/06/13)

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

-

, (2008/06/13)

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer''s disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer''s disease both prophylactically and therapeutically with such pharmaceutical compositions.

Lactam inhibitors of factor Xa and method

-

, (2008/06/13)

Lactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R10a, 1011 and R12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

-

, (2008/06/13)

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Reduction of azides to amines or amides with zinc and ammonium chloride as reducing agent

Lin, Wenqing,Zhang, Xiaomei,He, Ze,Jin, Yi,Gong, Liuzhu,Mi, Aiqiao

, p. 3279 - 3284 (2007/10/03)

Alkyl azides and acyl azides were reduced to the corresponding amines and amides with zinc and ammonium chloride as reducing agent under mild conditions in good to excellent yield.

MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS

-

, (2008/06/13)

The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

1,3-Disubstituted benzazepines as neuropeptide Y Y1 receptor antagonists

Murakami, Yasushi,Hagishita, Sanji,Okada, Tetsuo,Kii, Makoto,Hashizume, Hiroshi,Yagami, Tatsuroh,Fujimoto, Masafumi

, p. 1703 - 1714 (2007/10/03)

A novel class of potent and selective non-peptide neuropeptide Y (NPY) Y1 receptor antagonists, having benzazepine nuclei, have been designed, synthesized, and evaluated for activity. Through a blind screening we found the compound 1-N-(3-(N' -(tert-butoxycarbonyl)amino)benzyl)-7-methoxy-3-(3)-methylureido)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one (9: IC50 =1.6 μM). Chemical modifications of 9 gave a potent NPY Y1 antagonist 3-(N-(4-hydroxyphenyl)-N0 -methylguanidino)-1-N-(3-(N'-(tert- butoxycarbonyl)amino)benzyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one (14c: IC50 =43 nM), which had no affnity for NPY Y2 and Y5 receptors. (C) 1999 Elsevier Science Ltd. All rights reserved.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 86499-35-6